Arvinas

10 clinical trials to watch in the first half of 2025
BioPharma Dive
Thu, 01/2/25 - 11:42 am
clinical trials
Eli Lilly
cardiovascular disease
Arvinas
protein degradation
Vera Therapeutics
IgA nephropathy
Novarts
pelacarsen
Entyvio
IBD
Novo Nordisk
Alzheimer's disease
Beam Therapeutics
sickle cell disease
COMPASS Pathways
psychedelics
Moderna Therapeutics
Verve Therapeutics
high cholesterol
Pharma’s ‘it’ therapy — a new drug class gaining steam
Pharma Voice
Wed, 09/4/24 - 11:30 am
protein degradation
Arvinas
Merck KGaA
Sanofi
Pfizer
Novartis
Pfizer, Arvinas Post Upbeat Data From Breast Cancer Study
NASDAQ
Thu, 05/16/24 - 09:54 pm
Pfizer
Arvinas
clinical trials
vepdegestrant
Ibrance
breast cancer
Novartis pays $150M for Arvinas' phase 3-ready prostate cancer protein degrader
Fierce Biotech
Thu, 04/11/24 - 11:56 am
Novartis
Arvinas
protein degradation
prostate cancer
Pfizer's $1B protein degradation bet yields 3% response rate in Arvinas' midphase breast cancer trial
Fierce Biotech
Tue, 11/22/22 - 11:00 am
Pfizer
protein degradation
Arvinas
clinical trials
breast cancer
ARV-471
AstraZeneca's Alexion, Arvinas nab space at future 10-story biotech tower in New Haven
Fierce Biotech
Mon, 04/18/22 - 10:48 am
AstraZeneca
Alexion
Arvinas
Connecticut
ASCO-GU – Arvinas sees the path to a prostate cancer niche
EP Vantage
Wed, 02/16/22 - 10:26 am
Arvinas
ARV-110
prostate cancer
ASCO-GU
Licensing deals rack up in 2021
EP Vantage
Fri, 12/10/21 - 10:46 am
licensing
GSK
Alector
Novartis
BeiGene
Pfizer
Arvinas
iTeos Therapeutics
Bristol Myers Squibb
Eisai
The search for a better Faslodex continues
EP Vantage
Mon, 07/26/21 - 10:12 pm
breast cancer
drug development
Serds
Pfizer
Arvinas
Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table
Fierce Biotech
Thu, 07/22/21 - 11:15 am
Pfizer
Arvinas
breast cancer
protein degradation
biobucks
ASCO: Arvinas unveils first-in-human data for novel protein degrader in prostate cancer
Fierce Biotech
Thu, 05/14/20 - 11:56 am
ASCO 2020
Arvinas
ARV-110
protein degradation
prostate cancer
2 Biotech Stocks That Soared Last Week
Motley Fool
Mon, 10/28/19 - 10:34 am
Biogen
Arvinas
aducanumab
protein degradation
ARV-110
Big Pharma Bets on Body’s Garbage-Disposal System to Beat Cancer
Bloomberg
Thu, 10/10/19 - 07:55 pm
cancer
Arvinas
Kymera
targeted protein degradation
Bayer inks Arvinas deal to develop protein degraders
Fierce Biotech
Tue, 06/4/19 - 11:56 am
Bayer
Arvinas
targeted protein degradation
Nasdaq triple IPO play brings in $345M as the big biotech party rocks on
Endpoints
Thu, 09/27/18 - 11:55 am
NASDAQ
IPOs
Entasis
Urovant Sciences
Arvinas
Sutro BioPharma
Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs
Xconomy
Thu, 08/30/18 - 11:46 pm
biotech
IPOs
Sutro BioPharma
Arvinas
cancer
Pfizer lines up an $830M alliance with Arvinas on protein degradation
Endpoints
Thu, 01/4/18 - 11:23 am
Pfizer
Arvinas
targeted protein degradation
drug development
Genentech inks $650M deal with protein degradation pioneer Arvinas
Endpoints
Wed, 11/15/17 - 11:10 am
Genentech
targeted protein degradation
Arvinas
R&D
From big biopharma to biotech CEO, John Houston’s R&D journey highlights a fast-changing world
Endpoints
Wed, 09/20/17 - 09:23 am
R&D
John Houston
Big Pharma
biotech
Arvinas
GSK
Bristol-Myers Squibb
The 2015 Fierce 15 biotech execs take a bow
Fierce Biotech
Sat, 10/3/15 - 02:01 pm
Alector
Arvinas
CRISPR Therapeutics
Intellia Therapeutics
NGM Biopharmaceuticals
Padlock Therapeutics
SQZ Biotech
Revolution Medicines
Syros Pharmaceuticals
Unum Therapeutics
Yumanity Therapeutics

Pages